2/6
10:36 am
halo
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
Low
Report
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
2/3
12:01 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
2/2
11:45 pm
halo
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]
Low
Report
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]
1/31
07:03 pm
halo
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders [Yahoo! Finance]
Medium
Report
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders [Yahoo! Finance]
1/29
10:05 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/28
12:26 pm
halo
Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s [Yahoo! Finance]
Low
Report
Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s [Yahoo! Finance]
1/28
12:18 pm
halo
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript [Seeking Alpha]
1/28
06:46 am
halo
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance [Yahoo! Finance]
Medium
Report
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance [Yahoo! Finance]
1/28
06:30 am
halo
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Medium
Report
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
1/27
05:13 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
1/24
02:41 pm
halo
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 [Yahoo! Finance]
Low
Report
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 [Yahoo! Finance]
1/24
02:26 am
halo
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance [Yahoo! Finance]
Low
Report
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance [Yahoo! Finance]
1/20
04:05 pm
halo
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
Low
Report
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
1/20
02:56 pm
halo
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade [Yahoo! Finance]
Low
Report
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade [Yahoo! Finance]
1/19
03:26 pm
halo
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks [Yahoo! Finance]
Low
Report
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks [Yahoo! Finance]
1/10
07:02 pm
halo
How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]
1/10
03:36 am
halo
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]
Low
Report
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]
1/9
07:03 pm
halo
HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
1/8
07:05 pm
halo
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® [Yahoo! Finance]
Low
Report
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® [Yahoo! Finance]
1/8
01:32 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.
1/8
08:00 am
halo
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
Medium
Report
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
1/7
08:35 am
halo
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience [Yahoo! Finance]
Low
Report
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience [Yahoo! Finance]
1/5
07:13 am
halo
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity [Yahoo! Finance]
Low
Report
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity [Yahoo! Finance]
1/5
07:00 am
halo
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Low
Report
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
1/1
03:38 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 [Yahoo! Finance]